Legend Biotech Corporation American Depositary Shares (LEGN)
Legend Biotech Corporation (LEGN) Q2 2026 Earnings Call Transcript
Legend Biotech Corporation (LEGN) Q2 2026 Earnings Call Transcript
Legend Biotech Gains 6% on Q2 Earnings Beat as Adjusted EPS Doubles Consensus
Shares of Legend Biotech (NASDAQ:LEGN | LEGN Price Prediction) are climbing 6% to $21.88 Tuesday midday after the company reported Q2 2026 results that paired a solid revenue beat with the first quarter of company-wide profitability in its history.
Legend Biotech Q2 Earnings Call Highlights
Legend Biotech NASDAQ: LEGN reported second-quarter 2026 results marked by continued global growth for CARVYKTI and the company's first quarter of company-wide profitability on both an IFRS and adjusted basis, management said during its earnings call.
Legend Biotech: Why I'm Ready To Go Long Again
On July 15, J&J, a Legend Biotech Corporation partner, announced continued strong demand for Carvykti. Sales of this CAR-T cell therapy were $657 million in the second quarter, up 10.1% quarter-on-quarter and 49.7% year-on-year. Legend hasn't yet announced when it will publish its second-quarter report, but given Carvykti's sales, I expect it to beat consensus estimates.
Legend Biotech Jumps 42% On New Data -- Here's What Comes Next
Legend Biotech (LEGN) remains a buy as Carvykti's earlier-line use drives superior efficacy, safety, and manufacturing success, signaling a structural shift in multiple myeloma therapy. Recent CARTITUDE-4 data show earlier Carvykti use extends progression-free and overall survival, with Parkinsonism rates falling below 1%, reinforcing its clinical and commercial momentum. LB2102's early Phase 1 results in solid tumors, with up to 28.6% ORR and manageable toxicity, offer promising optionality beyond hematologic cancers, though confirmation in larger trials is needed.
Legend Biotech Corporation (LEGN) Shareholder/Analyst Call Transcript
Legend Biotech Corporation (LEGN) Shareholder/Analyst Call Transcript
Legend Biotech Conference Spotlights CARVYKTI's Curative Potential, Earlier Use
Legend Biotech NASDAQ: LEGN used an investor and analyst event to highlight long-term data and physician perspectives supporting broader use of CARVYKTI, its BCMA-directed CAR T-cell therapy for multiple myeloma developed, manufactured and co-promoted with Johnson & Johnson.
Legend Biotech Corporation (LEGN) Q1 2026 Earnings Call Transcript
Legend Biotech Corporation (LEGN) Q1 2026 Earnings Call Transcript
Legend Biotech Q1 Earnings Call Highlights
Legend Biotech NASDAQ: LEGN reported sharply higher first-quarter 2026 sales for CARVYKTI, its CAR T therapy for multiple myeloma, as management said demand continued to move into earlier lines of treatment and international markets expanded.
Legend Biotech (LEGN) Moves 18.4% Higher: Will This Strength Last?
Legend Biotech (LEGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Capital International Investors Sells 140,873 Shares of Legend Biotech Corporation Sponsored ADR $LEGN
Capital International Investors decreased its stake in shares of Legend Biotech Corporation Sponsored ADR (NASDAQ: LEGN) by 13.0% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 941,600 shares of the company's stock after selling 140,873 shares during the quarter. Capital
Legend Biotech Corporation (LEGN) Q4 2025 Earnings Call Transcript
Legend Biotech Corporation (LEGN) Q4 2025 Earnings Call Transcript
